Use of severely steatotic grafts in liver transplantation: A matched case-control study

Annals of Surgery

Volumn 246, Issue 6, 2007, Pages 940-946

  McCormack, Lucas ^a   Petrowsky, Henrik ^a   Jochum, Wolfram ^a   Mullhaupt, Beat ^a   Weber, Markus ^a   Clavien, Pierre Alain ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; FATTY LIVER; GRAFT DYSFUNCTION; GRAFT SURVIVAL; HISTOLOGY; HUMAN; HUMAN TISSUE; INTENSIVE CARE UNIT; ISCHEMIA; LENGTH OF STAY; LIVER GRAFT; LIVER TRANSPLANTATION; LIVING DONOR; MORTALITY; PRIORITY JOURNAL; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; BIOPSY; BIOPSY, NEEDLE; EUROPE; FATTY LIVER; FOLLOW-UP STUDIES; GRAFT SURVIVAL; HUMANS; LIVER FAILURE; LIVER TRANSPLANTATION; MIDDLE AGED; PREVALENCE; QUESTIONNAIRES; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 36549063731     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/SLA.0b013e31815c2a3f     Document Type: Article

References (35)

1. Registry ELT. http://www.eltr.org. Accessed 2006.
2. Network TOPaT. http://www.optn.org. Accessed 2006.
3. Kadry Z, Mc Cormack L, Clavien PA. Should living donor liver transplantation be part of every liver transplant program? J Hepatol. 2005;43:32-37.
4. Busuttil RW, Tanaka K. The utility of marginal donors in liver transplantation. Liver Transpl. 2003;9:651-663.
5. Clavien PA, Petrowsky H, DeOliveira ML, et al. Strategies for safer liver surgery and partial liver transplantation. N Engl J Med. 2007;356:1545-1559.
6. Merion RM, Goodrich NP, Feng S. How can we define expanded criteria for liver donors? J Hepatol. 2006;45:484-488.
7. Feng S, Goodrich NP, Bragg-Gresham JL, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant. 2006;6:783-790.
8. Verran D, Kusyk T, Painter D, et al. Clinical experience gained from the use of 120 steatotic donor livers for orthotopic liver transplantation. Liver Transpl. 2003;9:500-505.
9. Fishbein TM, Fiel MI, Emre S, et al. Use of livers with microvesicular fat safely expands the donor pool. Transplantation. 1997;64:248-251.
10. Zamboni F, Franchello A, David E, et al. Effect of macrovescicular steatosis and other donor and recipient characteristics on the outcome of liver transplantation. Clin Transplant. 2001;15:53-57.
11. Cameron A, Busuttil RW. AASLD/ILTS transplant course: is there an extended donor suitable for everyone? Liver Transpl. 2005;11(suppl 2):S2-S5.
12. Wiesner RH. Patient selection in an era of donor liver shortage: current US policy. Nat Clin Pract Gastroenterol Hepatol. 2005;2:24-30.
13. Strasberg SM, Howard TK, Molmenti EP, et al. Selecting the donor liver: risk factors for poor function after orthotopic liver transplantation. Hepatology. 1994;20(pt 1):829-838.
14. Loinaz C, Gonzalez EM. Marginal donors in liver transplantation. Hepatogastroenterology. 2000;47:256-263.
15. Imber CJ, St Peter SD, Lopez I, et al. Current practice regarding the use of fatty livers: a trans-Atlantic survey. Liver Transpl. 2002;8:545-549.
16. Pokorny H, Langer F, Herkner H, et al. Influence of cumulative number of marginal donor criteria on primary organ dysfunction in liver recipients. Clin Transplant. 2005;19:532-536.
17. McCormack L, Selzner M, Clavien P-A. The transplant operation. In: Killenberg P, Clavien P-A, eds. Medical Care of Liver Transplantation. Malden, MA: Blackwell Publishing Ltd.; 2006:229-241.
18. Briceno J, Solorzano G, Pera C. A proposal for scoring marginal liver grafts. Transpl Int. 2000;13(suppl 1):S249-S252.
19. Adam R, Bismuth H, Diamond T, et al. Effect of extended cold ischaemia with UW solution on graft function after liver transplantation. Lancet. 1992;340:1373-1376.
20. Bedossa P. [Presentation of a grid for computer analysis for compilation of histopathologic lesions in chronic viral hepatitis C. Cooperative study of the METAVIR group-]. Ann Pathol. 1993;13:260-265.
21. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205-213.
22. Ploeg RJ, D'Alessandro AM, Knechtle SJ, et al. Risk factors for primary dysfunction after liver transplantation - a multivariate analysis. Transplantation. 1993;55:807-813.
23. Yoong KF, Gunson BK, Neil DA, et al. Impact of donor liver microvesicular steatosis on the outcome of liver retransplantation. Transplant Proc. 1999;31:550-551.
24. De Carlis L, Colella G, Sansalone CV, et al. Marginal donors in liver transplantation: the role of donor age. Transplant Proc. 1999;31:397-400.
25. Selzner M, Clavien PA. Fatty liver in liver transplantation and surgery. Semin Liver Dis. 2001;21:105-113.
26. Nocito A, El-Badry AM, Clavien PA. When is steatosis too much for transplantation? J Hepatol. 2006;45:494-495.
27. El-Badry AM, Moritz W, Contaldo C, et al. Prevention of reperfusion injury and microcirculatory failure in macrosteatotic mouse liver by omega-3 fatty acids. Hepatology. 2007;45:855-863.
28. Todo S, Demetris AJ, Makowka L, et al. Primary nonfunction of hepatic allografts with preexisting fatty infiltration. Transplantation. 1989;47:903-905.
29. Canelo R, Braun F, Sattler B, et al. Is a fatty liver dangerous for transplantation? Transplant Proc. 1999;31:414-415.
30. Cameron AM, Ghobrial RM, Yersiz H, et al. Optimal utilization of donor grafts with extended criteria: a single-center experience in over 1000 liver transplants. Ann Surg. 2006;243:748-753; discussion 753-755.
31. Fukumori T, Ohkohchi N, Tsukamoto S, Satomi S. Why is a liver with steatosis susceptible to cold ischemic injury? Transplant Proc. 1999;31:548-549.
32. Mirza DF, Gunson BK, Da Silva RF, et al. Policies in Europe on "marginal quality" donor livers. Lancet. 1994;344:1480-1483.
33. Selzner N, Selzner M, Jochum W, et al. Mouse livers with macrosteatosis are more susceptible to normothermic ischemic injury than those with microsteatosis. J Hepatol. 2006;44:694-701.
34. Tullius SG, Volk HD, Neuhaus P. Transplantation of organs from marginal donors. Transplantation. 2001;72:1341-1349.
35. Machicao VI, Krishna M, Bonatti H, et al. Hepatitis C recurrence is not associated with allograft steatosis within the first year after liver transplantation. Liver Transpl. 2004;10:599-606.